MindPod pioneers the world’s first immersive neuro-animation experience
News
New asthma drug approved on NHS branded a ‘wonder drug’
Dupilumab (also known as Dupixent) will be available to patients through injections
Silence Therapeutics announces siRNA collaboration with Hansoh Pharma
Under the terms of the agreement, Hansoh will make a $16m upfront payment to Silence
Sensyne Health and OMNY Health sign agreement to support AI research
Sensyne and OMNY have agreed to work together on commercial projects for life sciences clients to advance ethical medical research
NICE clears Opdivo for resected oesophageal or gastro-oesophageal junction cancer
There are around 200 people in England who are eligible for this treatment
Phase III trial shows AZ’s liver cancer combination improves overall survival
Patients in the trial were those with unresectable hepatocellular carcinoma (HCC) who had not received systemic therapy treatment previously, and were not eligible for localised treatment
Entry still open for 2021 Marketer of the Year, Sales and Communications Awards!
Entry closes on 22nd October – so don’t miss out on your chance to enter now
Innovate UK funded NA-ATTC adds three new industry partners
The ATTC is coordinated as part of the Cell and Gene Therapy Catapult, and operates within the NHS framework
FDA clears Keytruda for first-line cervical cancer
Keytruda plus chemotherapy demonstrated superior overall survival rate in this patient population in the KEYNOTE-826 trial
NHS publishes new plans to improve patient access to GP appointments
The measures include a £250m ‘winter access fund’ from NHS England
New WHO group could be ‘the last to find virus origins’
26 experts have been appointed to join the Scientific Advisory Group on the Origins of Novel Pathogens (Sago)
SMC accepts Cabometyx/Opdivo combo for advanced kidney cancer patients
In a Phase III study, the risk of death for advanced RCC patients was decreased by 34% with Cabometyx plus Opdivo treatment
Sanofi’s BTK inhibitor tolebrutinib shows ‘promising’ long-term MS data
Tolebrutinib reduced multiple sclerosis (MS) disease activity as measured by MRI
MHRA backs Merck’s MET inhibitor Tepmetko
Conditional marketing authorisation granted for patients with advanced NSCLC with METex14 skipping alterations
Amgen reveals new combination data for KRAS inhibitor
Phase Ib CodeBreaK study evaluated Lumakras in over ten different investigational combination regimens
